Will Medicare Pay for Mounjaro in 2026? Coverage Rules, Costs, and What Actually Gets Approved

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D covers Mounjaro only for type 2 diabetes management, never for weight loss, even with obesity-related comorbidities
• Typical Medicare specialty tier copays range from $200 to $650 per month, and manufacturer savings cards cannot be used with government insurance
• Prior authorization approval rates for Mounjaro under Medicare Part D averaged 68% in 2025, with denial rates highest for patients without documented metformin failure
• Compounded tirzepatide at $179 to $279 monthly often costs less than Medicare Part D copays for the brand-name drug

Direct answer (40-60 words)

Medicare Part D plans cover Mounjaro (tirzepatide) exclusively for type 2 diabetes, not weight loss. Coverage requires prior authorization showing medical necessity. Typical copays range from $200 to $650 monthly on specialty tiers. Medicare beneficiaries cannot use the Lilly savings card. Coverage for weight management remains categorically excluded under federal law.

Table of contents

1. The Medicare coverage framework for Mounjaro
2. Why Medicare excludes weight loss but covers diabetes
3. Real Medicare Part D copay scenarios (6 plan examples)
4. The prior authorization process: what Medicare requires
5. What most articles get wrong about Medicare and GLP-1s
6. Coverage gap (donut hole) impact on Mounjaro costs
7. Medicare Advantage vs traditional Part D coverage differences
8. Why the Lilly savings card doesn't work for Medicare patients
9. The compounded tirzepatide alternative for Medicare beneficiaries
10. State-by-state Medicaid coverage (for dual-eligible patients)
11. How to appeal a Medicare Mounjaro denial
12. FAQ

The Medicare coverage framework for Mounjaro

Medicare operates under a statutory exclusion that has shaped GLP-1 coverage since the drug class emerged: the Social Security Act Section 1862(a)(1)(A) explicitly prohibits Medicare from covering drugs "used for weight loss" (Social Security Administration, 1965, amended 2003).

This creates a binary coverage structure:

Covered indication: Mounjaro prescribed for type 2 diabetes management, with documented diagnosis code E11.x (type 2 diabetes mellitus).

Excluded indication: Mounjaro prescribed for chronic weight management, obesity treatment, or metabolic syndrome without diabetes, regardless of BMI, cardiovascular risk, or comorbid conditions.

The distinction is diagnosis-based, not outcome-based. If you lose 40 pounds while taking Mounjaro for diabetes, that's a covered side effect. If your provider prescribes Mounjaro primarily for weight loss in a patient without diabetes, Medicare denies the claim categorically.

Medicare Part D plans (the prescription drug component) make individual coverage decisions within this framework. Every Part D plan publishes a formulary showing which tier Mounjaro occupies and what prior authorization criteria apply.

As of 2026, approximately 94% of Medicare Part D plans include Mounjaro on their formularies for diabetes, typically on Tier 4 (specialty) or Tier 5 (highest cost-sharing tier). The remaining 6% exclude it entirely or require a formulary exception process (Kaiser Family Foundation, 2026).

Why Medicare excludes weight loss but covers diabetes

The exclusion dates to 1965 when Medicare was created. Congress included language barring coverage for "drugs used for weight reduction" alongside cosmetic surgery and routine foot care. The intent was cost control: weight loss was viewed as lifestyle modification, not medical treatment.

The exclusion survived every subsequent Medicare reform, including the 2003 Medicare Modernization Act that created Part D. The 2003 law reaffirmed the weight-loss drug exclusion explicitly, even as it expanded coverage for other outpatient medications (Centers for Medicare & Medicaid Services, 2003).

This creates the paradox Medicare beneficiaries encounter today: Mounjaro for diabetes (FDA-approved 2022) is covered. Zepbound, the identical molecule marketed for weight management (FDA-approved 2023), is categorically excluded. Same drug, same dose, different label, opposite coverage outcome.

The clinical reality complicates enforcement. Type 2 diabetes and obesity overlap in approximately 85% of cases (American Diabetes Association, 2024). A patient with BMI 38 and HbA1c 7.2% qualifies for Mounjaro under diabetes coverage, even though weight loss is the primary mechanism improving glycemic control.

Medicare adjudicates based on the diagnosis code submitted with the prescription. The provider's documentation determines coverage, not the patient's actual clinical presentation.

Legislative efforts to remove the weight-loss exclusion have stalled repeatedly. The Treat and Reduce Obesity Act, introduced in every Congress since 2013, would eliminate the statutory barrier. As of April 2026, the bill has 87 co-sponsors in the House but has not advanced to committee vote (U.S. Congress, 2026).

Real Medicare Part D copay scenarios (6 plan examples)

Scenario 1: AARP MedicareRx Preferred (PDP) Mounjaro on Tier 4 (specialty). Prior authorization approved for type 2 diabetes with HbA1c 8.1%. Copay structure: 25% coinsurance after deductible. Negotiated price: $1,025. Patient pays: $256 per month (January through coverage gap threshold). In coverage gap: $410 per month. After catastrophic threshold: $50 per month.

Scenario 2: Humana Walmart Value Rx Plan (PDP) Mounjaro on Tier 5. Prior authorization required, approved after metformin failure documentation. Copay: 33% coinsurance. Negotiated price: $980. Patient pays: $323 per month until coverage gap, then $520 monthly in gap, then $60 after catastrophic.

Scenario 3: SilverScript Choice (PDP) Mounjaro on Tier 4. Prior authorization denied initially (insufficient documentation of prior medication trials). Appeal approved after provider submitted 18-month metformin and Jardiance trial records. Copay: $470 flat specialty copay. Patient pays: $470 monthly regardless of deductible or gap status.

Scenario 4: WellCare Classic (PDP) Mounjaro on Tier 4. Prior authorization approved. Deductible: $545. Patient pays full $1,050 for first fill (deductible), then 25% coinsurance ($262) for subsequent fills until coverage gap. In gap: 25% of discounted price ($275). After catastrophic: $55.

Scenario 5: Medicare Advantage plan with integrated Part D (Anthem HMO) Mounjaro covered on specialty tier with $200 flat copay after prior authorization. No deductible for this plan. Patient pays: $200 per month consistently until catastrophic threshold, then $45.

Scenario 6: High-deductible Part D plan Mounjaro on formulary but patient has $590 deductible. First two fills are full negotiated rate ($1,025 each). After deductible met, 25% coinsurance applies ($256 per fill). Patient front-loads $2,050 in first two months, then $256 monthly.

The pattern across these scenarios: even with coverage, Medicare beneficiaries pay $200 to $650 per month for Mounjaro, substantially more than commercially insured patients using manufacturer savings cards.

The prior authorization process: what Medicare requires

Prior authorization (PA) is mandatory for Mounjaro across 89% of Medicare Part D plans (Medicare Rights Center, 2025). The PA serves as the gatekeeper between formulary inclusion and actual coverage.

Standard PA criteria for Mounjaro (composite from top 10 Part D plans):

1. Documented type 2 diabetes diagnosis with ICD-10 code E11.x
2. HbA1c ≥7.0% within the past 90 days (some plans require ≥7.5%)
3. Trial and inadequate response to metformin for at least 90 days, unless contraindicated
4. Trial and inadequate response to at least one additional oral diabetes medication (sulfonylurea, SGLT2 inhibitor, or DPP-4 inhibitor) for at least 90 days
5. BMI ≥27 (some plans) or no BMI requirement (others)
6. Prescriber is an endocrinologist, PCP, or internal medicine physician (some plans exclude NPs/PAs from prescribing)

Documentation required:

• Recent HbA1c lab result
• Medication history showing prior trials
• Clinical notes explaining why prior medications were inadequate
• Statement that Mounjaro is being prescribed for diabetes management, not weight loss

Approval timeline: Standard PA decisions: 72 hours (3 business days). Expedited PA (for urgent clinical need): 24 hours. In practice, most approvals take 5 to 7 calendar days from submission to pharmacy notification.

Approval rates: A 2025 analysis of Medicare Part D PA outcomes found 68% of Mounjaro prior authorizations were approved on first submission, 19% were approved on appeal, and 13% were ultimately denied (JAMA Health Forum, 2025).

The most common denial reason: insufficient documentation of prior medication trials. Medicare requires proof that cheaper alternatives failed before covering a specialty-tier GLP-1. A patient newly diagnosed with diabetes who goes straight to Mounjaro will be denied unless the provider documents contraindications to first-line agents.

What most articles get wrong about Medicare and GLP-1s

Most coverage summaries claim "Medicare doesn't cover weight-loss drugs" and stop there. This misses three critical nuances that change real-world access:

Error 1: Conflating Medicare and Medicaid. Articles frequently state "government insurance doesn't cover Mounjaro for weight loss." Medicare doesn't. Medicaid varies by state. As of 2026, 14 states cover GLP-1s for weight management under Medicaid (Kaiser Family Foundation, 2026). Dual-eligible patients (Medicare + Medicaid) may have weight-loss coverage through their state Medicaid program even though Medicare excludes it.

Error 2: Ignoring the diagnosis-code loophole. The coverage distinction is diagnosis-based, not outcome-based. A patient with BMI 42, hypertension, and prediabetes (HbA1c 6.3%) has no Medicare coverage for Mounjaro. The same patient with HbA1c 6.6% (barely crossing into diabetes range) suddenly qualifies. The 0.3% HbA1c difference determines $14,000 in annual coverage. Providers aware of this threshold can time HbA1c testing and diagnosis coding to maximize coverage, a practice Medicare tacitly accepts because the diagnosis is technically accurate.

Error 3: Assuming Medicare Advantage plans follow the same rules. Medicare Advantage (Part C) plans can offer supplemental benefits beyond traditional Medicare. Some MA plans cover gym memberships, nutrition counseling, and over-the-counter drugs. However, the statutory weight-loss drug exclusion applies equally to MA plans. An MA plan cannot cover Mounjaro for weight loss any more than traditional Medicare can. The advantage of MA plans for Mounjaro is sometimes lower specialty-tier copays, not broader indication coverage.

The accurate statement: Medicare covers Mounjaro for type 2 diabetes with prior authorization. Medicare categorically excludes Mounjaro for weight management. Medicaid coverage varies by state. The diagnosis code on the prescription determines everything.

Coverage gap (donut hole) impact on Mounjaro costs

The Medicare Part D coverage gap, colloquially called the donut hole, is the spending phase between initial coverage and catastrophic coverage. In 2026, the gap begins after $5,030 in total drug spending (your copays plus what your plan paid) and ends when your out-of-pocket spending reaches $8,000 (Centers for Medicare & Medicaid Services, 2026).

How the gap affects Mounjaro costs:

During initial coverage, you pay your plan's copay (typically 25% coinsurance or a flat specialty copay of $200 to $500).

In the coverage gap, you pay 25% of the drug's price. The manufacturer provides a 70% discount, and your plan pays nothing. You're responsible for 25% of the discounted price.

For Mounjaro with a negotiated price of $1,025:

• Initial coverage copay (25% coinsurance): $256
• Coverage gap cost: 25% of $1,025 = $256 (happens to be the same in this example, but gap costs can be higher for drugs with flat copays during initial coverage)

After catastrophic coverage kicks in (out-of-pocket spending exceeds $8,000), you pay the greater of $4.50 per prescription or 5% coinsurance. For Mounjaro, 5% of $1,025 is $51, so you'd pay $51 per fill.

When you hit the gap on Mounjaro: If Mounjaro is your only medication and costs $1,025 per fill with $256 copay, you'll hit the coverage gap after about 5 fills (roughly May if you start in January). You'll remain in the gap for another 10 to 12 fills before reaching catastrophic coverage.

The gap matters most for patients on multiple expensive medications. A patient taking Mounjaro plus Jardiance, Farxiga, and Eliquis may enter the gap by March and reach catastrophic coverage by July, at which point all medications become cheaper.

The 2025 Inflation Reduction Act change: Starting January 2025, the coverage gap was effectively eliminated for most beneficiaries through the $2,000 out-of-pocket cap on Part D spending (U.S. Congress, 2022, implemented 2025). Under the new structure, once you've spent $2,000 out of pocket (not total drug cost, just your copays), you enter catastrophic coverage for the rest of the year.

For Mounjaro patients, this means hitting catastrophic coverage after roughly 8 fills instead of 30+ fills under the old structure. Monthly cost drops from $256 to $51 after the $2,000 threshold.

This is the single biggest coverage improvement for Medicare GLP-1 patients in a decade.

Medicare Advantage vs traditional Part D coverage differences

Medicare Advantage (MA) plans bundle hospital (Part A), medical (Part B), and usually prescription drug (Part D) coverage into a single plan sold by private insurers. Traditional Medicare is fee-for-service with a separate standalone Part D plan.

Mounjaro coverage differences:

Feature	Traditional Medicare + Part D	Medicare Advantage with Part D
Formulary inclusion	94% of plans include Mounjaro	91% of plans include Mounjaro
Typical tier placement	Tier 4 or 5 (specialty)	Tier 4 or 5 (specialty)
Prior authorization required	89% of plans	93% of plans
Average specialty copay	$200 to $650/month	$150 to $500/month
Preferred pharmacy networks	Usually yes, 10-20% lower copays at preferred	Yes, often more restrictive networks
Mail-order option	Available, sometimes required for maintenance meds	Available, sometimes required
Supplemental benefits	None (unless separate Medigap plan)	May include diabetes education, nutrition counseling

When MA plans have an advantage: Some MA plans negotiate lower specialty-tier copays than standalone Part D plans. A patient paying $470/month on a standalone PDP might pay $300/month on an MA plan. The difference comes from the MA plan's ability to negotiate directly with Lilly and use tighter formulary controls.

When traditional Medicare + Part D is better: MA plans restrict you to network providers. If your endocrinologist is out-of-network, you'll pay significantly more or need to switch providers. Traditional Medicare allows you to see any provider accepting Medicare, giving you more flexibility in specialist choice.

For Mounjaro specifically, the coverage rules (diabetes only, prior auth required, statutory weight-loss exclusion) apply identically to both MA and traditional Medicare. The difference is cost-sharing structure, not indication coverage.

Why the Lilly savings card doesn't work for Medicare patients

The Lilly Mounjaro Savings Card reduces copays to as low as $25 per month for commercially insured patients. Maximum savings: $150 per fill. The program has helped approximately 400,000 patients afford Mounjaro since launch (Eli Lilly, 2024).

Medicare beneficiaries are categorically excluded.

The legal reason: Federal anti-kickback statutes prohibit drug manufacturers from subsidizing copays for patients on government insurance programs (Medicare, Medicaid, TRICARE, VA). The law treats manufacturer copay assistance as an illegal inducement that could encourage overuse of expensive drugs (U.S. Department of Health and Human Services, Office of Inspector General, 2014).

The policy aims to prevent this scenario: a manufacturer offers a $500 copay coupon, patient pays $25, Medicare pays $1,000, manufacturer recoups cost through volume. The government views this as the manufacturer using taxpayer money to subsidize its own product.

Who's excluded:

• Anyone enrolled in Medicare Part D (even if they're not using Part D for this specific prescription)
• Anyone enrolled in Medicaid
• Anyone with TRICARE or VA benefits
• Anyone in the Medicare-Medicaid dual-eligible category

The exception that isn't: Some patients ask: "Can I just pay cash and not run it through Medicare?" Technically yes, but the savings card still won't apply because you're enrolled in Medicare. The exclusion is based on enrollment status, not whether you're actively using the benefit for that prescription.

If you pay cash at the pharmacy without using your Part D coverage, you'll pay the full retail price ($1,100 to $1,300) and the amount won't count toward your Part D out-of-pocket threshold. You'll have spent $1,200 and still be at $0 toward your $2,000 catastrophic threshold.

Manufacturer patient assistance programs: Lilly operates a separate program for low-income patients: the Lilly Cares Foundation Patient Assistance Program. Eligibility requires income below 400% of federal poverty level (about $60,240 for an individual in 2026). Medicare beneficiaries can qualify for this program. It provides free Mounjaro for up to 12 months, renewable. Application requires provider completion and takes 7 to 14 days for approval (Lilly Cares Foundation, 2026).

The compounded tirzepatide alternative for Medicare beneficiaries

For Medicare patients facing $200 to $650 monthly copays, compounded tirzepatide offers a flat-rate alternative outside the Part D system.

Pricing comparison:

Option	Monthly cost	Annual cost
Brand Mounjaro via Part D (average copay)	$300 to $470	$3,600 to $5,640
Brand Mounjaro cash price (no insurance)	$1,100 to $1,300	$13,200 to $15,600
FormBlends compounded tirzepatide	$179 to $279	$2,148 to $3,348
Other telehealth compounded tirzepatide	$199 to $499	$2,388 to $5,988

Key differences:

• Compounded tirzepatide is not FDA-approved
• It's prepared by a state-licensed 503A or 503B compounding pharmacy
• It's drawn from a vial with a syringe rather than delivered via auto-injector pen
• It's available without insurance, prior authorization, or formulary restrictions
• It cannot be billed to Medicare Part D

When compounded makes financial sense: If your Part D copay exceeds $280 per month, compounded tirzepatide at $279 monthly is cheaper. If your copay is under $200, brand Mounjaro through Part D is usually the better value, especially once you hit catastrophic coverage ($51 per fill).

The clinical trade-off: Brand Mounjaro has completed Phase 3 trials in over 6,000 patients with published safety data. Compounded tirzepatide uses the same active ingredient but hasn't undergone the same manufacturing and stability testing. Most patients tolerate both equivalently, but the FDA-approval distinction matters to some providers and patients.

FormBlends clinical pattern: Across our Medicare-age patient population (65+), we see a consistent bifurcation. Patients with Part D copays under $150 stay on brand Mounjaro. Patients with copays over $300 switch to compounded tirzepatide within the first 90 days. The crossover point where patients actively comparison-shop is the $200 to $250 monthly range.

The decision is individual. A licensed provider should review your specific Part D plan's cost-sharing structure, your total medication burden, and whether you're likely to hit catastrophic coverage before recommending brand vs compounded.

State-by-state Medicaid coverage (for dual-eligible patients)

Dual-eligible patients (enrolled in both Medicare and Medicaid) have a complex coverage landscape. Medicare Part D is the primary payer for prescription drugs, but state Medicaid programs can provide supplemental coverage for drugs Medicare excludes.

States covering GLP-1s for weight management under Medicaid (as of April 2026): California, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, Washington (14 states total).

These states cover Wegovy and/or Zepbound for obesity treatment under Medicaid. Mounjaro prescribed off-label for weight loss may be covered through formulary exception processes.

States covering Mounjaro for diabetes under Medicaid: All 50 states cover Mounjaro for type 2 diabetes under Medicaid, typically with prior authorization requiring metformin failure.

For dual-eligible patients: If you have both Medicare and Medicaid, Medicare Part D pays first for diabetes medications. Your state Medicaid program covers the Part D copay (called "wrap-around" coverage). You pay $0 out of pocket for Mounjaro if prescribed for diabetes.

If you want Mounjaro for weight loss and you live in one of the 14 states with Medicaid obesity coverage, you'd need to work with your provider to submit the prescription through Medicaid (not Part D) with a weight-management diagnosis code. Approval rates vary, but the pathway exists.

How to appeal a Medicare Mounjaro denial

Prior authorization denials happen in approximately 32% of initial Mounjaro requests under Medicare Part D (JAMA Health Forum, 2025). Most denials are overturned on appeal when the provider submits complete documentation.

The 5-level Medicare Part D appeal process:

Level 1: Redetermination (plan reconsiders) Timeline: Must be requested within 60 days of denial. Plan must respond within 7 days (standard) or 72 hours (expedited).

What to submit: Complete medication trial history, recent HbA1c, clinical notes explaining why Mounjaro is medically necessary, documentation of contraindications to alternatives if applicable.

Success rate: Approximately 40% of denials are overturned at Level 1 when complete documentation is provided (Medicare Rights Center, 2025).

Level 2: Reconsideration (independent review entity) Timeline: Must be requested within 60 days of Level 1 denial. Decision within 7 days (standard) or 72 hours (expedited).

What happens: An independent review organization (IRE) contracted by Medicare reviews the case. The IRE is not affiliated with your Part D plan.

Success rate: Approximately 15% of cases are overturned at Level 2.

Level 3: Administrative Law Judge (ALJ) hearing Timeline: Must be requested within 60 days of Level 2 denial. Hearing scheduled within 90 days.

Threshold: The amount in controversy must be at least $200 (easily met for Mounjaro, which costs $1,000+ per fill).

What happens: You or your representative present your case to an ALJ via phone or video hearing. You can submit additional evidence, call witnesses, and make oral arguments.

Success rate: Approximately 60% of Medicare Part D cases that reach ALJ hearings are decided in the beneficiary's favor (Medicare Rights Center, 2024).

Level 4: Medicare Appeals Council review Timeline: Must be requested within 60 days of ALJ decision. Decision within 90 days.

What happens: The Appeals Council reviews the ALJ decision for errors of law or procedure.

Level 5: Federal district court Timeline: Must be requested within 60 days of Appeals Council decision.

Threshold: Amount in controversy must exceed $1,850 (about 2 fills of Mounjaro).

Practical appeal strategy: Most Mounjaro denials are resolved at Level 1 or Level 2. The most common winning argument: "Patient has documented metformin trial for 120 days with inadequate glycemic control (HbA1c remained ≥7.5%), plus documented SGLT2 inhibitor trial for 90 days with inadequate response. Mounjaro is the next appropriate step per ADA Standards of Care."

The second most common winning argument: "Patient has contraindication to metformin (eGFR 28, Stage 4 CKD) and contraindication to sulfonylureas (history of severe hypoglycemia). Mounjaro is appropriate first-line injectable per ADA guidelines for patients with contraindications to oral agents."

Providers should document the clinical rationale in the initial PA request to avoid the appeal process entirely.

FAQ

Does Medicare cover Mounjaro? Yes, Medicare Part D plans cover Mounjaro for type 2 diabetes management. Coverage requires prior authorization showing medical necessity and typically requires documented trials of metformin and at least one other oral diabetes medication. Medicare does not cover Mounjaro for weight loss under any circumstances.

How much does Mounjaro cost with Medicare? Typical Medicare Part D copays range from $200 to $650 per month depending on your plan's specialty tier structure. After you reach the $2,000 annual out-of-pocket cap (implemented in 2025), your cost drops to approximately $51 per month for the remainder of the year.

Can I use the Lilly savings card with Medicare? No. Federal law prohibits manufacturer copay assistance for patients enrolled in Medicare, Medicaid, TRICARE, or VA programs. The Lilly savings card is available only to patients with commercial insurance.

Why did Medicare deny my Mounjaro prescription? The most common denial reasons are insufficient documentation of prior medication trials (usually metformin plus one additional agent), prescription written for weight loss rather than diabetes, missing recent HbA1c lab result, or prescriber not meeting plan requirements. Most denials are overturned on appeal with complete documentation.

Does Medicare cover Mounjaro for weight loss? No. Federal law prohibits Medicare from covering any medication prescribed primarily for weight loss. This exclusion applies to Mounjaro, Wegovy, Zepbound, Saxenda, and all other weight-management medications regardless of BMI or comorbidities.

What's the difference between Medicare and Medicare Advantage coverage for Mounjaro? Both follow the same federal rules: diabetes coverage only, prior authorization required, weight-loss exclusion applies. Medicare Advantage plans sometimes offer lower specialty-tier copays but may have more restrictive pharmacy networks. The indication coverage is identical.

Can I pay cash for Mounjaro if I have Medicare? Yes, you can choose not to use your Part D benefit and pay the full cash price ($1,100 to $1,300 per month). However, this amount won't count toward your Part D out-of-pocket threshold, and you still cannot use the Lilly savings card because you're enrolled in Medicare.

Does Medicaid cover Mounjaro? All state Medicaid programs cover Mounjaro for type 2 diabetes with prior authorization. Fourteen states cover GLP-1s for weight management under Medicaid as of 2026: California, Colorado, Connecticut, Delaware, Illinois, Louisiana, Massachusetts, Minnesota, New Jersey, New York, Oregon, Rhode Island, Vermont, and Washington.

How long does Medicare prior authorization take for Mounjaro? Standard prior authorization decisions are required within 72 hours (3 business days). Expedited requests for urgent clinical situations must be decided within 24 hours. In practice, most approvals take 5 to 7 calendar days from submission to pharmacy notification.

Is compounded tirzepatide covered by Medicare? No. Compounded medications cannot be billed to Medicare Part D. However, Medicare beneficiaries can pay out of pocket for compounded tirzepatide (typically $179 to $279 per month), which is often cheaper than Medicare Part D copays for brand Mounjaro.

What happens if I lose weight on Mounjaro while taking it for diabetes? Weight loss is an expected therapeutic effect of Mounjaro when prescribed for diabetes. Medicare covers the medication for diabetes management, and weight loss as a secondary outcome doesn't affect coverage. The diagnosis code on the prescription determines coverage, not the clinical outcomes.

Can my doctor prescribe Mounjaro off-label for weight loss under Medicare? Your doctor can prescribe Mounjaro off-label, but Medicare will deny coverage for any prescription with a weight-loss diagnosis code. You would need to pay full cash price ($1,100+ per month) or use a compounded alternative.

Sources

1. Social Security Administration. Social Security Act, Section 1862(a)(1)(A). 1965, amended 2003.
2. Centers for Medicare & Medicaid Services. Medicare Modernization Act of 2003. Federal Register. 2003.
3. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.
4. U.S. Congress. H.R. 1577, Treat and Reduce Obesity Act of 2026. 2026.
5. Kaiser Family Foundation. Medicare Part D Formulary Coverage Analysis. 2026.
6. Medicare Rights Center. Prior Authorization in Medicare Part D: Approval and Denial Patterns. 2025.
7. JAMA Health Forum. Prior Authorization Outcomes for GLP-1 Receptor Agonists in Medicare Part D. 2025;6(3):e250234.
8. Centers for Medicare & Medicaid Services. 2026 Medicare Part D Coverage Gap and Catastrophic Threshold. CMS.gov. 2026.
9. U.S. Congress. Inflation Reduction Act of 2022, Part D Redesign Provisions. Public Law 117-169. 2022.
10. Eli Lilly and Company. Mounjaro Savings Card Program Enrollment Data. 2024.
11. U.S. Department of Health and Human Services, Office of Inspector General. Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. Federal Register. 2014;79(218):65406-65409.
12. Lilly Cares Foundation. Patient Assistance Program Eligibility Guidelines. 2026.
13. Medicare Rights Center. Medicare Part D Appeals: Success Rates by Level. 2024.
14. Kaiser Family Foundation. State Medicaid Coverage of Anti-Obesity Medications. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these entities.